Today, ExpreS2ion Biotechnologies’ CEO Bent U. Frandsen and CFO Keith Alexander presented the results and update on business for the third quarter of 2024. Furthermore, they gave some insight into the latest developments in the pipeline including the term sheet agreement on the malaria candidate and progress on the CMV candidate.

ExpreS2ion Biotechnologies is expected to release its Q3 2024 results on 14 November 2024. Later the same day at 11:00, the company’s CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements during the period in an online live presentation. The management presentation will be followed by a Q&A session.

In connection with this month's two announcements on Malaria commercialization and reverse share split, we sat down with the company’s CEO Bent Frandsen to get more flavor on these news.

The company's main project is ES2B-C001. A HER2+ therapeutic vaccine for breast cancer, currently preparing for Phase I trials in early 2025. But the company previously contributed to the successful development of a Phase III validated COVID-19 booster vaccine, licensed by Bavarian Nordic.

Enters interesting partnership with Serum Institute of India Private Limited (SIIPL) on malaria.